<DOC>
	<DOCNO>NCT01280396</DOCNO>
	<brief_summary>Second-generation antipsychotic ( SGAs ) , include clozapine , commonly use nowadays treatment psychosis . There increase concern relate metabolic side-effects weight gain , risk cause glucose intolerance hyperlipidemia , specific condition know metabolic syndrome . All side-effects might associate increase risk cardiovascular disease diabetes mellitus . This study analyze simple physical measurement ( weight height ) venous blood test ( fast blood glucose lipid ) result collect routinely since 2008 ( recommend local hospital authority territory-wide `` SGAs Monitoring Program '' ) outpatients receive SGAs ( amisulpride , aripiprazole , olanzapine , paliperidone , quetiapine , risperidone ziprasidone ) and/or clozapine , local psychiatric outpatient clinic Hong Kong . The investigator hypothesize differential risk metabolic side-effects amongst SGAs .</brief_summary>
	<brief_title>Metabolic Side-effects Second-generation Antipsychotics</brief_title>
	<detailed_description />
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Clozapine</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>â‰¥18 year age outpatients receive one antipsychotic : aripiprazole , amisulpride , clozapine , olanzapine , paliperidone , quetiapine , risperidone , ziprasidone consent provide physical measurement venous blood sample consent provide venous blood sample and/or physical measurement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>metabolic</keyword>
	<keyword>SGAs</keyword>
	<keyword>clozapine</keyword>
</DOC>